TY - JOUR
T1 - Borneol alleviates oxidative stress via upregulation of Nrf2 and Bcl-2 in SH-SY5Y cells
AU - Hur, J.
AU - Pak, Sokcheon
AU - Koo, B-S
AU - Jeon, S.
N1 - Imported on 12 Apr 2017 - DigiTool details were: month (773h) = January, 2013; Journal title (773t) = Pharmaceutical Biology. ISSNs: 1388-0209;
PY - 2013/1
Y1 - 2013/1
N2 - Context: The ß-amyloid (Aß) peptide aggregation with accompanying oxidative stress plays the major role in the pathogenesis of Alzheimer's disease (AD). Some natural compounds, including borneol, shed promising light on AD treatment. Objective: The present study was designed to investigate the antioxidative, antiapoptotic effects, and neuroprotection of borneol in human neuroblastoma cells (SH-SY5Y). Materials and methods: Oxidative stress was induced by administering 50 'M Aß into SH-SY5Y cells. Neuroprotective effect of commercially available borneol was examined by determining cell viability with the MTT assay. Intracellular reactive oxygen species (ROS) generation was measured using a fluorometer with further examination of heme oxygenase-1 (HO-1) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) expression. Apoptosis was examined by measuring the ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax). Results: Our data indicated that Aß-induced cell cytotoxicity was inhibited by 100 'M of (-) and (+) borneol treatment. Treatment of borneol significantly decreased ROS generation (P < 0.01). The expression of HO-1 and nuclear translocation of Nrf2 were increased by Aß treatment. This nuclear translocation of Nrf2 was further increased by administration of borneol. Compared with the Aß treated group, the (+) borneol treated group significantly increased Bcl-2 expression with decreased expression of Bax. Discussion and conclusion: Borneol protected SH-SY5Y cells against Aß-induced toxicity, exerted an antioxidative effect and suppressed apoptosis. It increases our knowledge about neuroprotective mechanism of borneol, and it is hopeful to be a candidate compound for developing therapeutic drug for the prevention and treatment of AD and other Aß-related neurodegenerative diseases.
AB - Context: The ß-amyloid (Aß) peptide aggregation with accompanying oxidative stress plays the major role in the pathogenesis of Alzheimer's disease (AD). Some natural compounds, including borneol, shed promising light on AD treatment. Objective: The present study was designed to investigate the antioxidative, antiapoptotic effects, and neuroprotection of borneol in human neuroblastoma cells (SH-SY5Y). Materials and methods: Oxidative stress was induced by administering 50 'M Aß into SH-SY5Y cells. Neuroprotective effect of commercially available borneol was examined by determining cell viability with the MTT assay. Intracellular reactive oxygen species (ROS) generation was measured using a fluorometer with further examination of heme oxygenase-1 (HO-1) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) expression. Apoptosis was examined by measuring the ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax). Results: Our data indicated that Aß-induced cell cytotoxicity was inhibited by 100 'M of (-) and (+) borneol treatment. Treatment of borneol significantly decreased ROS generation (P < 0.01). The expression of HO-1 and nuclear translocation of Nrf2 were increased by Aß treatment. This nuclear translocation of Nrf2 was further increased by administration of borneol. Compared with the Aß treated group, the (+) borneol treated group significantly increased Bcl-2 expression with decreased expression of Bax. Discussion and conclusion: Borneol protected SH-SY5Y cells against Aß-induced toxicity, exerted an antioxidative effect and suppressed apoptosis. It increases our knowledge about neuroprotective mechanism of borneol, and it is hopeful to be a candidate compound for developing therapeutic drug for the prevention and treatment of AD and other Aß-related neurodegenerative diseases.
U2 - 10.3109/13880209.2012.700718
DO - 10.3109/13880209.2012.700718
M3 - Article
C2 - 23134284
SN - 1388-0209
VL - 51
SP - 30
EP - 35
JO - Pharmaceutical Biology
JF - Pharmaceutical Biology
IS - 1
ER -